Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 57.17%
March 31, 2026 52.89%
December 31, 2025 21.20%
September 30, 2025 61.75%
June 30, 2025 68.50%
March 31, 2025 97.76%
December 31, 2024 82.65%
September 30, 2024 83.81%
June 30, 2024 43.55%
March 31, 2024 87.32%
December 31, 2023 87.29%
September 30, 2023 90.29%
June 30, 2023 83.42%
March 31, 2023 86.18%
December 31, 2022 92.24%
September 30, 2022 94.53%
June 30, 2022 94.71%
March 31, 2022 55.21%
December 31, 2021 86.76%
September 30, 2021 96.95%
June 30, 2021 88.49%
March 31, 2021 94.79%
December 31, 2020 88.52%
September 30, 2020 87.44%
June 30, 2020 88.11%
Date Value
March 31, 2020 93.29%
December 31, 2019 95.40%
September 30, 2019 90.91%
June 30, 2019 0.00%
March 31, 2019 91.25%
December 31, 2018 93.46%
September 30, 2018 79.79%
June 30, 2018 0.00%
March 31, 2018 0.00%
December 31, 2017 0.00%
September 30, 2017 0.00%
June 30, 2017 0.00%
March 31, 2017 0.00%
December 31, 2016 0.00%
September 30, 2016 0.00%
June 30, 2016 0.00%
March 31, 2016 0.00%
December 31, 2015 0.00%
September 30, 2015 0.00%
June 30, 2015 0.00%
March 31, 2015 0.00%
December 31, 2014 0.00%
September 30, 2014 0.00%
June 30, 2014 0.00%
March 31, 2014 0.00%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 54.97%
Corcept Therapeutics, Inc. 98.41%
Veru, Inc. --
Johnson & Johnson 73.00%
Eli Lilly & Co. 85.78%

Gross Profit Margin (Quarterly) Related Metrics